

Effect of Single Dose of Secnidazole in Treatment of Intestinal Amoebiasis

Pages with reference to book, From 159 To 159

Gh. Omrani, M. Khamseh (Shiraz University of Medical Sciences, Tehran, Iran.)

A. Rastegar-Lari (University of Medical Sciences, Tehran, Iran.)

Introduction

Nitroimidazoles are highly potent antiprotozoal agents with well- established indications. Since the discovery of metronidazole, a member of this group, the treatment of amoebiasis has been revolutionized^{1,2}. Despite its extreme potency against *E-histolytica*, metronidazole has to be taken for a relatively long period (10 days) and has various side effects including headache, metallic taste, nausea, diarrhoea and abdominal discomfort. Treatment failure are relatively common due to poor patient compliance³. Another nitroimidazole, namely (hydroxy-2-propyl) 1-methyl-2- nitro-5-imidazole, (Secnidazole), with a molecular weight of 184.18, is the first of group which offers a 3-day antiprotozoal effect from a single dose. This pharmacokinetic characteristic explains the good activity of secnidazole against intestinal amoebiasis. We tried secnidazole in the treatment of intestinal amoebiasis in Shahid Faghihi Hospital of Shiraz.

Patients, Methods and Results

Twenty-two patients (mean age 32 years) with dysentery, tenesmus and bloody stool which were positive for trophozoite of *E. histolytica*, were entered in the study. Seven asymptomatic carriers (mean age 38 years) were also included. Results of physical examination and pre-treatment symptoms such as abdominal pain, loose stool and hematochezia were recorded in detail. Stool specimens obtained were examined microscopically and cultured to confirm the diagnosis of acute and chronic amoebiasis. All patients were given 2 grains (4 tablets of 500 mg) of secnidazole in a single oral dose. They were instructed to record details of all complaints and side effects and were asked to return for re-examination and stool culture, three weeks after treatment. Responses to treatment were classified as "clinical cure" when all signs and symptoms disappeared and "parasitological cure" when stool cultures for amoeba were negative. Culture media were prepared with some modifications. Two cultures were used for each specimen. 30 mg of rice powder was added to both streptomycin and penicillins were added to just one of the media. Stool specimen was added to both media and incubated at 37°C for 24 hours.

Thirty-two patients (25 with acute and 7 with chronic amoebiasis) from Shahid Faghihi Hospital in Shiraz entered the study. Bloody stool (100%), abdominal pain (50%), tenesmus (45%) and bowel movement up to six times per day were the major complaints. Chronic carriers with cyst of *E. histolytica* in stool had no sign and symptom. After administration of secnidazole, there was significant improvement of symptoms. In all acute cases, the frequency of bowel movements decreased to once a day. Bloody stool and abdominal pain disappeared within 24-48 hours. On parasitological examination only 1 (16%) out of 7 patients with chronic amoebiasis had positive stool culture three weeks after treatment while all other were negative. None of the side effects which are common with nitroimidazole derivatives like nausea, vomiting, vertigo, ataxia and metallic taste, were observed in our patients.

Comments

Secnidazole, the newest among the nitroimidazole group, has a much longer half life compared to metronidazole, tinidazole and ornidazole⁴. The results of present study confirm the previous reports on effectiveness of single dose of secnidazole in relieving clinical symptoms with high parasitological cure rate in patients with acute and chronic amoebiasis⁵⁻⁹. However, compared to widely used drugs such as metronidazole with long duration of treatment and the side effects, which have significant disadvantages to their use¹⁰, secnidazole appears to be superior due to the single dose of the drug and better compliance and lack of untoward side effects.

Acknowledgements

Help of Professor M. Mahmoudian and Dr. M. Motevalian in preparation of this manuscript I gratefully acknowledged.

References

1. Rossigno!, J. F and Maionneuve, H. Nitroimidazoles in the treatment of trichomoniasis, giardiasis and amebiasis Int. J. Clin. Pharmacol. Ther. Toxicol., 1984;22:63-72.
2. Rosenblatt, J. E. and Eson, R. S. Metronidazole, Mayo Clin. Proc., 1987;62:1013-1015.
3. Roe, F. J. C. Metronidazole: Review of uses and toxicity. J. Antimicrob. Chemother., 1977;3:205-207.
4. Bassily, S., Farid, Z., Masry, N. A. et al. Treatment of intestinal *E. histolytica* and *G. lamblia* with metronidazole, tinidazole and ornidazole: A comparative study. J. Trop. Med. Hyg., 1987;90:9-12.
5. Andre, L. J. Clinical studies of secnidazole in acute intestinal amebiasis. Am. J. Gast. Hepat. 1979;15:221-225.
6. Soedin, K., Yukran, O. K., Fadillah, A. et al. Comparison between the efficacy of a single dose of secnidazole with a 5-days course of tetracycline and clioquinol in the treatment of acute intestinal amoebiasis. Pharmatherapeutica, 1985;4:251-54.
7. Sinuhji, A. B., Lubis, C. P., Daulay, H. R. et al. A double blind trial between metronidazole and secnidazole in acute amebic dysentery in children. (preliminary report) amebiasis Paediatr. Indones., 1986;26:9-12.
8. Cesari, M., Condat, M., Gendron, Y. et al. Traitement de l'amebiase par le secnidazole en cure courte. Med. Trop., 1982;52:527-529.
9. Latino, A. Efficacy of a single-dose secnidazole in the treatment of acute and chronic amebiasis. J. Trop. Med. Hyg., 1988;91:202-204.
10. Oren, B., Schgurcnsky, E., Epros, M. et al. Single-dose ornidazole versus seven-Dog Metronidazole therapy of giardiasis in Kibbutzim children. Europ. J. Clin. Microbiol. Infect. Dis. 1991 ;10:963- 965.